
Patients with inflammatory bowel disease have an increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD). The study aims to determine the prevalence of CVD and VTE risk factors in a large population of patients with ulcerative colitis (UC).We conducted a cross-sectional study in 33 French and Belgium referral centers. A questionnaire was developed to explore self-reported risk factors for VTE and CVD, based on the latest international guidelines, in consecutive patients with UC.A total of 1071 patients with UC were included. There were 539 women (50.3%), and the median age of patients was 44 years [32; 57]. The median disease duration was 10 years [6; 17]. In the cohort, 36.5% of patients reported no cardiovascular risk factor (CVRF) and 72% had ≤ 1 CVRF. Regarding cardiovascular risk markers (CVRM) 36.9% of patients reported no CVRM and 78% had ≤ 1 CVRM. Of the 1071 patients, 91.3% of patients reported no VTE strong risk factor and 96% had ≤ 1 VTE moderate risk factor.This is the first cohort specifically designed to assess both VTE and CVD risks in patients with UC. More than one third of patients with UC had no CVRF and around three quarters had ≤ 1 CVRF. In addition, more than nine out of ten patients had no VTE strong risk factor and ≤ 1 moderate risk factor. Physicians should be aware of these factors in their patients.
Adult, MESH: Self Report, 610, Ulcerative, Colitis, Ulcerative/complications/diagnosis/epidemiology, Sciences de la santé humaine, MESH: Venous Thromboembolism, MESH: Cross-Sectional Studies, MESH: Risk Factors, Risk Factors, MESH: Colitis, 616, Prevalence, Humans, Human health sciences, MESH: Prevalence, Heart disease risk factors, Disease progression, MESH: Humans, Venous thromboembolism., MESH: Cardiovascular Diseases, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Cardiovascular Diseases/complications/diagnosis/epidemiology, Gastroentérologie & hépatologie, Venous Thromboembolism, Venous Thromboembolism/diagnosis/epidemiology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Cross-Sectional Studies, Ulcerative colitis, Cardiovascular Diseases, Colitis, Ulcerative, Female, Self Report, MESH: Female, Gastroenterology & hepatology, Venous thromboembolism
Adult, MESH: Self Report, 610, Ulcerative, Colitis, Ulcerative/complications/diagnosis/epidemiology, Sciences de la santé humaine, MESH: Venous Thromboembolism, MESH: Cross-Sectional Studies, MESH: Risk Factors, Risk Factors, MESH: Colitis, 616, Prevalence, Humans, Human health sciences, MESH: Prevalence, Heart disease risk factors, Disease progression, MESH: Humans, Venous thromboembolism., MESH: Cardiovascular Diseases, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Cardiovascular Diseases/complications/diagnosis/epidemiology, Gastroentérologie & hépatologie, Venous Thromboembolism, Venous Thromboembolism/diagnosis/epidemiology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Cross-Sectional Studies, Ulcerative colitis, Cardiovascular Diseases, Colitis, Ulcerative, Female, Self Report, MESH: Female, Gastroenterology & hepatology, Venous thromboembolism
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
